A study to investigate the safety, tolerability, pharmacokinetics, and early signs of biological activity of danegaptide following oral administration in participants with diabetic macular edema
This study is looking at a new oral medicine called danegaptide for people who have diabetic macular edema. This is an eye condition caused by diabetes that can affect your vision. The main goals of this early-stage study are to check how safe the medicine is and if people can take it without too many side effects (this is called 'tolerability'). Researchers also want to understand how your body uses and gets rid of the medicine (this is called 'pharmacokinetics'). Finally, they are looking for any early hints that the medicine might be helping with the eye condition. It's a first step to see if danegaptide could be a helpful treatment in the future.
At a glance
What is this study about?
Diabetic macular edema is an eye problem that can happen to people with diabetes. It's when swelling occurs in the macula, which is the part of your eye responsible for sharp, central vision. This swelling can make it harder to see clearly, making everyday tasks like reading or driving difficult. Finding new and effective ways to treat this condition is very important to help people keep their good vision.
This particular study is focusing on a new medicine called danegaptide. It's designed to be taken by mouth, which could be a convenient option if it proves to be effective. Because this is an early study, the main things researchers are looking at are the safety of the medicine and if people can generally cope with taking it without too many unwanted effects. They also want to understand how the medicine moves through your body – how it's absorbed, distributed, processed, and eventually leaves your system. This helps them work out the best doses.
Beyond safety, the study is also looking for any early clues or 'biological activity' that show danegaptide might be starting to have an effect on diabetic macular edema. Think of it as a very first look to see if the medicine has the potential to help. If this early study shows promising results, it might lead to bigger studies in the future to confirm if it can genuinely improve vision for people with this eye condition.
Key takeaways
- This study evaluates a new oral medicine (danegaptide) for diabetic macular edema.
- It's an early-stage study primarily focused on safety and how the body handles the medicine.
- Researchers are also looking for early signs that the medicine might be beneficial for vision.
- Participation involves taking the medicine and attending regular clinic visits for health checks.
- Open to adults aged 18 and over, both men and women.
- Your decision to join or leave the study is entirely yours, without impacting your care.
Who may be eligible?
To be able to take part in this study, you generally need to be an adult, 18 years old or older. The study is open to both men and women.
Because this is an early-stage study for a specific eye condition called diabetic macular edema, it's very likely that you would need to have been diagnosed with this condition to be considered. The research team will have a more detailed list of criteria – things like certain health conditions or medicines you might be taking – that would decide if this study is right for you. They will review your medical history carefully to make sure it's safe for you to take part.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have diabetic macular edema?
- Are you able to attend study visits regularly?
- Are you willing to take a new study medicine by mouth?
- Are you comfortable with blood tests and eye examinations?
What does participation involve?
If you decide to take part in this study, you would be asked to attend several visits at the study clinic. During these visits, the research team would carry out different assessments. These might include eye exams to check your vision and the condition of your macula, blood tests, and other health checks to monitor your overall well-being. You would be given the study medicine, danegaptide, to take by mouth as directed. The team would explain exactly how and when to take it. There will be follow-up appointments to see how you are doing, track any side effects, and check for early signs of the medicine working. The total time you would be involved in the study would depend on the specific design, but early-stage studies often last several weeks to a few months.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What is diabetic macular edema?
It's an eye condition caused by diabetes where swelling occurs in the macula, a part of your eye needed for sharp central vision. This can make your vision blurry.
What is danegaptide?
Danegaptide is a new medicine being tested in this study. It's designed to be taken by mouth for people with diabetic macular edema.
What is a 'Phase I' study?
This is an early stage of research where doctors test a new medicine in people for the first time. The main goals are to check if it's safe, what dose might work, and how the body handles it.
Will this medicine cure my eye condition?
This early study is looking for initial signs that the medicine could be helpful. It's too soon to say if it will be a cure or a long-term treatment. More research would be needed.
Who is funding this research?
The study document doesn't provide information on funding. You can ask the research team for this detail if you're interested.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.